Acquired thrombotic thrombocytopenic purpura: New therapeutic options and their optimal use

Journal of Thrombosis and Haemostasis

Volumn 13, Issue S1, 2015, Pages S223-S229

  Cataland, S R ^a   Wu, H M ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

ADAMTS13 protein, human; Relapse; Rituximab; Thrombotic thrombocytopenic purpura; Von Willebrand factor

Indexed keywords

CAPLACIZUMAB; EGAPTIVON PEGOL; LACTATE DEHYDROGENASE; PLACEBO; RECOMBINANT ENZYME; RECOMBINANT VON WILLEBRAND FACTOR CLEAVING PROTEINASE; RITUXIMAB; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; VON WILLEBRAND FACTOR;

BLEEDING; CONTINUOUS INFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; HUMAN; INFUSION RELATED REACTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REMISSION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VON WILLEBRAND DISEASE; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; DEFICIENCY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYME REPLACEMENT; ENZYMOLOGY; MOLECULARLY TARGETED THERAPY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENT DISEASE; TREATMENT OUTCOME;

ADAM PROTEINS; ANIMALS; BLOOD COAGULATION; DRUG DISCOVERY; ENZYME REPLACEMENT THERAPY; FIBRINOLYTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECOMBINANT PROTEINS; RECURRENCE; REMISSION INDUCTION; RITUXIMAB; SPLENECTOMY; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 84931301411     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12934     Document Type: Review

References (25)

1. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
2. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-5.
3. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-44.
4. Cataland SR, Scully MA, Paskavitz J, Maruff P, Witkoff L, Jin M, Uva N, Gilbert JC, Wu HM. Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. Am J Hematol 2010; 86: 87-9.
5. Deford CC, Reese JA, Schwartz LH, Perdue JJ, Kremer Hovinga JA, Lammle B, Terrell DR, Vesely SK, George JN. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 2013; 122: 2023-9; quiz 142.
6. Kennedy AS, Lewis QF, Scott JG, Kremer Hovinga JA, Lammle B, Terrell DR, Vesely SK, George JN. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion 2009; 49: 1092-101.
7. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Investig 2005; 115: 2752-61.
8. Sadler JE. von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11-8.
9. Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, Wu HM. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008; 141: 651-8.
10. Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura: evidence-based focused review. Blood 2015; 125: 1526-31.
11. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815-22.
12. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Reti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-9.
13. Wu TC, Yang S, Haven S, Holers VM, Lundberg AS, Wu H, Cataland SR. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost 2013; 11: 1925-7.
14. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746-53.
15. Hie M, Gay J, Galicier L, Provot F, Presne C, Poullin P, Bonmarchand G, Wynckel A, Benhamou Y, Vanhille P, Servais A, Bordessoule D, Coindre JP, Hamidou M, Vernant JP, Veyradier A, Coppo P. French Thrombotic Microangiopathies Reference C. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 2014; 124: 204-10.
16. Westwood JP, Webster H, Mcguckin S, Mcdonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 2013; 11: 481-90.
17. Cataland SR, Jin M, Lin S, Kraut EH, George JN, Wu HM. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol 2008; 83: 911-5.
18. Kappers-Klunne MC, Wijermans P, Fijnheer R, Croockewit AJ, van der Holt B, de Wolf JT, Lowenberg B, Brand A. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005; 130: 768-76.
19. Cataland SR, Peyvandi F, Mannucci PM, Lammle B, Kremer Hovinga JA, Machin SJ, Scully M, Rock G, Gilbert JC, Yang S, Wu H, Jilma B, Knoebl P. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol 2012; 87: 430-2.
20. Holz JB. The TITAN trial-assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci 2012; 46: 343-6.
21. Peyvandi F, Duby C. Anti-Vwf nanobody potentially changing the treatment paradigm in thrombotic thrombocytopenic purpura: results of the TITAN trial. Blood 2014; 124: 0-0.
22. George JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004; 41: 60-7.
23. Schiviz A, Wuersch K, Piskernik C, Dietrich B, Hoellriegl W, Rottensteiner H, Scheiflinger F, Schwarz HP, Muchitsch EM. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood 2012; 119: 6128-35.
24. Plaimauer B, Kremer Hovinga JA, Juno C, Wolfsegger MJ, Skalicky S, Schmidt M, Grillberger L, Hasslacher M, Knobl P, Ehrlich H, Scheiflinger F. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011; 9: 936-44.
25. Jian C, Xiao J, Gong L, Skipwith CG, Jin SY, Kwaan HC, Zheng XL. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 2012; 119: 3836-43.